Nesidioblastosis After Gastric-Bypass Surgery Heidi Chamberlain Shea, MD Endocrine Associates of Dallas Case   47 year old male presents with recent onset of confusion Occurs 1-3 hours.

Download Report

Transcript Nesidioblastosis After Gastric-Bypass Surgery Heidi Chamberlain Shea, MD Endocrine Associates of Dallas Case   47 year old male presents with recent onset of confusion Occurs 1-3 hours.

Nesidioblastosis
After Gastric-Bypass Surgery
Heidi Chamberlain Shea, MD
Endocrine Associates of Dallas
Case


47 year old male presents with recent
onset of confusion
Occurs 1-3 hours after meals



Worse with high carbohydrate intake
Resolves when eats or drinks
carbohydrates
Blood sugar 53 mg/dl with confusion
Case


History of obesity
 Roux-en-Y-gastric
bypass 2 years ago
 BMI 45 to current 23
Glucose 53 mg/dl



Insulin 16 µU/ml (< 3)
C-peptide 1.8 ng/ml
(< 0.6)
Negative sulfonylurea
screen
Differential Diagnosis
Hypoglycemia

Non-Beta cell tumors







Sarcoma and fibroma
Adrenocortical
Hepatomas
Carcinoid
Hormonal deficiencies
Cortisol
Growth hormone
Critical illness

Mesechymal







Hepatic disease
Cardiac disease
Renal disease
Sepsis
Starvation
Alimentary (Reactive)

Post gastric-bypass


Dumping Syndrome
Idiopathic
Differential Diagnosis
Hypoglycemia

Drugs







Insulin
Sulfonylurea
Alcohol
Pentamidine
Quinine
Salicylates
Sulfonamides
Differential Diagnosis
Hypoglycemia

Metabolic disorders




Galactosemia
Fructose intolerance
Fatty acid oxidation
defects
Glycogen storage
disorders

Endogenous
hyperinsulinism



Insulinoma
Auto-antibodies to
insulin or the β-cell
Functional β-cell
disorder
Beta-cell Function
SUR 1 (Kir 6.2)
α-Ketoglutarate
GDH
Glutamate
Differential Diagnosis
Post-prandial Hypoglycemia








Drugs
Critical illness
Hormonal deficiencies
Non-Beta cell tumors
Endogenous
hyperinsulinism
Autoimmune
Metabolic
Alimentary (Reactive)
Case

Does he have an insulinoma?



Imaging



Triple phase spiral CT
Transabdominal ultrasound of the pancreas
Arterial calcium-stimulation testing


Should have fasting hypoglycemia
Only occurring after meals is unusual
Increased insulin from the splenic artery distribution
Underwent partial pancreatectomy
Histology
Normal islet
Hypertrophic islet cells
Insulin cells lining the pancreatic ducts
(Nesidioblastosis)
What is Nesidioblastosis?



Pathological description of islet
cells budding off pancreatic ducts
Hyperinsulinemic hypoglycemia
Affects the newborn population




Transient



Loss of function in Sur 1 (Kir 6.2)
Gain of function GDH and GK
Deletion of chromosome 11p150
Diazoxide
Octreotide
Persistent

Partial pancreatectomy
Hyperinsulinemia Hypoglycemia
From Gastric-Bypass?
Service et. al., NEJM 2005, 353(3):249-54
Hyperinsulinemia Hypoglycemia
In Adults?



45 cases in the literature
Earliest report 1975
Found due to surgical
resection for insulinoma




Postprandial
hypoglycemia
Neuroglycopenic
symptoms
Incidence
One case after pancreatic 
 Male = Female
transplant
No mutations in MEN 1,  Obese and lean
Sur1 or Kir6.2

Age

11 to 84 years
Questions


Does altering gastric
anatomy result in
hyperinsulinemia
hypoglycemia?
Is weight loss revealing
underlying pathology?
Points of Discussion



Discuss the interaction between hormones
and regulation of appetite
Review metabolic changes associated
with gastric by-pass surgery
Decide if gastric by-pass is a risk factor for
hyperinsulinemia hypoglycemia
Peptides, Hormones & Neurotransmitters
Effect On Eating
Orexigenic
Anorectic
Neuropeptide Y (Y1)
Serotonin
GABA (A)
Cholecystokinin
Norepinephrine (α2)
Dopamine (D2)
Glucocorticoid (type II)
Leptin
Galanin
Insulin
Opiods
TRH
Aldosterone (type I)
Calcitonin
Opiods
Bombesin
GHRH
VIP
Ghrelin
CRH
Neurotensin
CGRP
Glucagon
IL-1 and 2
TNF, Prostaglandin
Appetite Control
Wynne et. al., JCEM 2004, 89(6):2576-2582
Intestinal Regulation of Appetite

Ghrelin


Secreted from oxyntic
cells of stomach
Initiates hunger




Increases before meal
Decreases afterward
Increases calorie
intake
True role in
decreasing appetite is
debated
Intestinal Regulation of Appetite

Peptide YY (PYY)



Satiety and nutrient
absorption
Crosses blood brain barrier
Secreted from entire intestine




Greater in distal
L cells
Pancreatic polypeptide (PP)


Satiety and nutrient absorption
Produced by pancreas



Colon and rectum
Stimulated by food
More is released with later
meals of the day
Stimulated by food via vagal  Increased with anorexia
stimulation
 Variable levels seen with
Increased levels




High calorie
Fat
Inactivated by dipeptidyl
peptidase IV (DPPIV)
obesity
Intestinal Regulation of Appetite
Wynne et. al., JCEM 2004, 89(6):2576-2582
Intestinal Regulation of Appetite

Glucagon-like peptides
(GLP-1 & 2)


Satiety
Expressed in brain,
pancreas and small
intestine






L-cells
Stimulated by food
Acts via the GLP-1
receptor
Augments postprandial
insulin secretion
Decreases gastric motility
Inhibits gastric acid
secretion

Oxyntomodulin (OXM)


Satiety
Expressed in brain, and small
intestine







L-cells
Stimulated by food
Acts via the GLP-1 receptor
Augments postprandial
insulin secretion
Decreases gastric motility
Inhibits gastric acid secretion
Meal termination

Inhibits Ghrelin
Intestinal Regulation of Appetite

Cholecystokinin
(CCK)


Satiety and nutrient
absorption
Released by
duodenum and
jejunum


L cells
Stimulated by
intraluminal food
Bariatric Surgery
Gastric Banding
30-50% weight loss
Roux-en-Y-gastric bypass
50-80% weight loss
Bariatric Surgery





Most effective way to
achieve weight loss
Reduces weight by
35-40%
Maintained for 15
years
Decreases appetite
Malabsorption is
limited
Bariatric Surgery
Complications


Immediate post surgical
risks
Malabsorption

Limited time

Dumping syndrome







Nausea
Bloating
Colic
Diarrhea
Light headedness
Diaphoresis
Palpitations
Bariatric Surgery
Benefits

Improves obesity-related
comorbidities





Diabetes
Hypertension
Dyslipidemia
Nonalcoholic steatosis
Sleep apnea






Reflux esophagitis
Venous stasis ulcers
Infertility
Arthritis
Pseudotumor cerebri
Stress incontinence
Bariatric Surgery
Physiology
Banded
N=17
Control
N=17
Dixon et al., JCEM 2005, 90(2):813-19
Bariatric Surgery
Physiology
Glucose mg/dl
Insulin uIU/L
135
60
125
50
40
115
30
105
20
95
10
85
0700
0900
1000
1100
0700
0900
1000
1100
□ BMI matched controls N=17
●○ Lap band patients N=17
Dixon et al., JCEM 2005, 90(2):813-19
Gastric-bypass
Hormonal Changes

After bypass






Ghrelin variable
results
Leptin decreases
Glucose decreases
Insulin decreases
Adiponectin increases
CCK, VIP and
Serotonin unaffected
Gastric-bypass
Hormonal Changes

Future studies



Response of other
intestinal hormones
Understand the
complex interactions
between hormones
and appetite
Other unidentified
players?
Hyperinsulinemia Hypoglycemia
From Gastric-Bypass?
Service et. al., NEJM 2005, 353(3):249-54
β-cell Proliferation

Authors postulate that gastric-bypass
increases incretin like substances
Increased bolus delivery to distal small
intestine
 β-cells stimulated to increased insulin
secretion = hypertrophy


What happens to islet cells with incretin
supplementation?
Animal Studies
Exenatide


Non diabetic obese
male Zucker rats
3 groups

Control given saline


Exenatide treated and
PO ad lib


N=10
Pair fed


N=11
N=10
6 week study
Gedulin, B. R. et al. Endocrinology 2005;146:2069-2076
Animal Studies
Exenatide
Gedulin, B. R. et al. Endocrinology 2005;146:2069-2076
Animal Studies
Exenatide
● Ex
∆ PF
○ CL


Absolute mass
unchanged
No comment about
hypertrophy




Absolute β-cell mass
Improved sensitivity
Decrease in β-cell mass
No evidence for
hypertrophy in presence
of incretins
Gedulin, B. R. et al. Endocrinology 2005;146:2069-2076
Conclusions

Does altering gastric anatomy
result in hyperinsulinemia
hypoglycemia?


Is weight loss revealing
underlying pathology?



Currently no evidence to support
Possibly
Insulin resistance is protective
Patients that need surgery

Unknown defect in β-cell function
Hypoglycemia Trials
Are patients not identified?

Multiple studies
Patients are rarely hypoglycemic with
symptoms
 Normal non-symptomatic patient can be
hypoglycemia

Brun JF, et. al., Diabetologia 1995, 38(4)
 Palardy J et. al., NEJM 1989, 321(21)
 Buss RW et. al., Hormone & Metabolism Research
1982, 14(6)
 Lev-Rau et al, Diabetes 1981, 30(12)
